Bile Salts
Identity, Nomenclature, and Chemical Nature
Bile salts are a family of steroidal amphiphilic molecules that are the sodium and potassium ionic forms of bile acids. Bile acids are amphiphilic, water-soluble molecules that are mainly synthesized by the liver (primary forms) and by bacterial transformation in the colon (secondary forms). They are usually found as conjugates with taurine or glycine in the bile of mammals and vertebrates; the sodium and potassium salts of these negatively charged molecules are technically called bile salts, which is a more precise chemical designation. In common usage, however, the terms "bile acid" and "bile salt" are frequently used interchangeably.
The family of bile acids includes a group of molecular species of acidic steroids with very peculiar physical-chemical and biological characteristics. They are synthesized by the liver from cholesterol through several complementary pathways that are controlled by mechanisms involving fine-tuning by the levels of certain bile acid species. Although their best-known role is participation in the digestion and absorption of fat, they also play an important role in several other physiological processes.
Primary Bile Acids and Salts
The primary bile acids synthesized in the liver are cholic acid and chenodeoxycholic acid, which are typically conjugated to glycine or taurine before secretion. Following synthesis, the most abundant bile acids in human bile are chenodeoxycholic acid (CDCA), at approximately 45%, and cholic acid (CA), at approximately 31%. These are referred to as the primary bile acids. Chemically, cholic acid is 3α,7α,12α-trihydroxy-5β-cholanoic acid and chenodeoxycholic acid is 3α,7α-dihydroxy-5β-cholanoic acid.
Bile acids are synthesized in the liver by a multistep, multiorganelle pathway in which hydroxyl groups are inserted at specific positions on the steroid structure; the double bond of the cholesterol B ring is reduced; and the hydrocarbon chain is shortened by three carbons, introducing a carboxyl group at the end of the chain. There are at least 16 enzymes that catalyse up to 17 reactions to convert insoluble cholesterol into a highly soluble conjugated bile salt. At least one transporter and multiple cellular compartments — including the cytosol, endoplasmic reticulum, mitochondria, and peroxisomes — are involved.
Conjugated Forms (Bile Salts Proper)
Prior to secreting any of the bile acids, liver cells conjugate them with either glycine or taurine, to form a total of eight possible conjugated primary bile acids. These conjugated bile acids are often referred to as bile salts. Glycine conjugation to cholic acid generates glycocholic acid (GCA), whereas taurine conjugation yields taurocholic acid (TCA). The pKa of the unconjugated bile acids is between 5 and 6.5, and the pH of the duodenum ranges between 3 and 5, so when unconjugated bile acids are in the duodenum they are almost always protonated, making them relatively insoluble in water. Conjugating bile acids with amino acids lowers the pKa of the bile-acid/amino-acid conjugate to between 1 and 4, greatly improving their solubility and function in the intestinal environment.
Secondary Bile Acids
A limited pool of bile acids that is not reabsorbed in the small intestine undergoes dehydroxylation and deconjugation in the large intestine by bacterial enzymes, leading to the formation of the secondary bile acids, deoxycholic acid (DCA) from cholic acid, and lithocholic acid (LCA) from CDCA. Bile acids realize their effects through nuclear farnesoid X receptors (FXRs) and membrane TGR5 receptors. They are also associated with other receptors, including the vitamin D receptor (VDR), the pregnane X receptor (PXR), and potentially the constitutive androstane receptor (CAR).
Supplement Sources and Common Forms
Bile salt supplements are derived primarily from animal sources or produced synthetically. The most common commercial forms include:
- Ox bile extract: The primary bile acids found in ox bile are conjugated forms of cholic acid and chenodeoxycholic acid. These are chemically similar to the bile acids produced by the human body, making them relevant in supporting natural digestive processes. The content of pure bile acids in ox bile is about 40%, and some supplements may be purified to contain higher amounts.
- Tauroursodeoxycholic acid (TUDCA): TUDCA is a taurine conjugated form of ursodeoxycholic acid (UDCA) with higher hydrophilicity. TUDCA is currently marketed in Italy under the brand name Tudcabil and is exported to China and Turkey under the brand name Taurolite, where it is used for the treatment of cholesterol gallstones.
- Ursodeoxycholic acid (UDCA / ursodiol): The application of bile acids for gallstone dissolution, and of ursodeoxycholic acid for cholestatic liver diseases, began in the second half of the 20th century. Currently, UDCA is regarded as an effective first-line treatment for primary biliary cholangitis and is also applied in other cholestatic disorders, including primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.
TUDCA has been licensed for the treatment of cholesterol gallstones and for therapy of chronic cholestatic liver disease in Europe since 1991, at a dose of 10–20 mg/kg/day depending on the indication.
Traditional and Historical Use
Animal bile has been regarded as a potential remedy for liver diseases for millennia in ancient Eastern cultures. The use of animal bile for medicinal purposes dates back centuries. Ancient Egyptians, Greeks, and Romans utilized various animal biles, including ox bile, to treat ailments related to digestion, liver problems, and even skin conditions.
Traditional Chinese Medicine
Ox bile supplements have a long history of medicinal use in traditional Chinese medicine (TCM). Historical records indicate that the use of ox bile dates back to the Zhou dynasty (c. 1046–256 BCE), when it was one of the first animal biles, alongside dog and common carp bile, employed in TCM. Over the centuries, a total of forty-four different animal biles — including those from both invertebrates and vertebrates, and even humans — have been used to treat a wide array of ailments. These biles were principally prescribed for liver and biliary diseases, skin conditions (including burns), gynecological and heart diseases, and disorders of the eyes, ears, nose, mouth, and throat.
Bile from many different animals were recorded in traditional Chinese medicine beginning in the Zhou dynasty from 1046–256 BCE. These bile acids were used for the treatment of gallstones, infectious skin diseases or burns, vision and eye conditions, respiratory infections, and even coma and epilepsy. Biles mentioned in TCM books are from the common carp fish, goat, sheep, mouse, shark, wild boar, elephant, tiger, and even from pythons and venomous vipers. Ox bile was used in combination with gentian root, other herbs, and honey to combat jaundice, or applied on the skin for hemorrhoids.
Greco-Roman Traditions
The use of bile as a medicine dates back to ancient Greek and Roman times, where it was associated with the theory of the four humors. "Choler" (yellow bile) and "black bile" were considered vital fluids that needed to remain in balance for health. Ox bile, in particular, was believed to influence digestion and temperament and was sometimes used in remedies for sluggishness, melancholy, and digestive troubles.
Western Pharmacopoeial and 19th–20th Century Use
During the 19th and early 20th centuries, ox bile was widely incorporated into compound medicines, particularly in Europe and the United States, as a treatment for chronic dyspepsia, liver congestion, and fatty liver conditions. In the 19th and 20th centuries, Western medicine began to investigate the physiological role of bile acids, leading to the development of purified bile extracts for therapeutic use. Early pharmaceutical preparations often included ox bile or bile salts to assist with fat digestion, especially for patients with liver or gallbladder issues.
Key Constituents and Active Compounds
Bile salts are composed of the salts of four different kinds of free bile acids — cholic, deoxycholic, chenodeoxycholic, and lithocholic acids — and each of these acids may in turn combine with glycine or taurine to form more complex acids and salts.
Both bile acid and bile salt forms have hydroxyl groups that are α in orientation (lying "below" the plane of the rings) and methyl groups that are β (lying "above" the plane of the rings). The molecules therefore have both a polar and a nonpolar face, enabling them to act as emulsifying agents in the intestine, helping prepare dietary triacylglycerol and other complex lipids for degradation by pancreatic digestive enzymes.
The principal conjugated bile salts found in human bile include:
- Chenodeoxycholic acid (CDCA) and cholic acid (CA) — the two primary bile acids in humans — are conjugated mainly to glycine and taurine.
- Glycine conjugation to cholic acid generates glycocholic acid (GCA), whereas taurine conjugation yields taurocholic acid (TCA).
- The major bile salts of humans found predominantly in bile include cholic acid derivatives — taurocholic acid (TCA) and glycocholic acid — and chenodeoxycholic acid (CDCA) derivatives — taurochenodeoxycholic acid and glycochenodeoxycholic acid.
Established Mechanisms of Action
Fat Emulsification and Micellar Solubilization
Bile, a product of the liver, contains bile salts which emulsify fat: the bile salts act as a detergent to split fat particles in the diet into smaller globules so that they remain suspended in water in the form of an emulsion. This exposes substantially more of the fat surface area to the enzyme lipase, so that the digestion process is enhanced.
When fat enters the small intestine, bile salts arrange themselves around triglyceride droplets to form micelles — tiny spherical structures with fat at the center and water-compatible surfaces facing outward. This micellar packaging is what allows pancreatic lipase to access and hydrolyze triglycerides into fatty acids and monoglycerides. The same micellar phase carries fat-soluble vitamins A, D, E, and K to the intestinal wall for absorption. Without adequate bile, fat passes through incompletely digested and fat-soluble vitamin absorption drops accordingly.
Enterohepatic Circulation
More than 95% of the bile acid pool is reabsorbed from the intestine, predominantly by an active sodium-dependent apical bile acid transporter (ASBT) in the terminal ileum, and transported back to the liver bound mainly to albumin and to a lesser extent to lipoproteins. The more abundant conjugated bile acids require an apical sodium-dependent bile acid transporter in the terminal ileum to cross the brush border membrane of the enterocytes, before they are assisted across the enterocyte by a heterodimer of two proteins, termed organic solute transporters (OSTα and OSTβ), which are responsible for driving bile acids through the basolateral membranes and into the venous blood.
Nuclear Receptor Signaling: FXR
Next to their role in digestion of dietary fats, bile salts function as signaling molecules for bile salt receptors such as Farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5). Complementary to their role in metabolism, FXR and TGR5 are shown to play a role in intestinal homeostasis and immune regulation.
FXR activation exerts profound effects on hepatic metabolism. It downregulates the expression of liver X receptor (LXR) and sterol regulatory element-binding protein 1c (SREBP-1c), leading to a reduction in fatty acid and triglyceride synthesis in the liver. This mechanism contributes to the attenuation of steatogenesis and gluconeogenesis. Concurrently, FXR upregulates hepatic glycogen synthesis through the activation of fibroblast growth factor (FGF) 15/19, PPARγ, GLUT-4, and GLP-1, collectively improving insulin sensitivity.
Membrane Receptor Signaling: TGR5
Beyond the orchestration of bile acid, lipid, and glucose metabolism by FXR, bile acids also act as signaling molecules through the bile acid-dedicated G-protein coupled receptor (GPCR) TGR5 (GPR131). Stimulation of the TGR5 signaling pathway confers to bile acids the ability to modulate energy expenditure by controlling the activity of type 2 deiodinase and the subsequent activation of thyroid hormone in brown adipose tissue (BAT) and muscle.
Bile acids have been shown to activate TGR5 in intestinal L cells and enhance secretion of glucagon-like peptide 1 (GLP-1) to potentiate insulin secretion in response to glucose. TGR5 activation induces Dio2 gene expression, which converts thyroxine (T4) to tri-iodothyronine (T3), resulting in increased energy expenditure. In addition to Dio2, numerous genes involved in thermogenesis are increased by TGR5 activation, including PGC1α, PGC1β, UCP1, and UCP3.
Intestinal Barrier and Immune Function
While certain bile acids may exert detrimental effects on the gut, they are vital for preserving the integrity of the gut barrier. They play a significant role in cell proliferation and apoptosis, regulate both mucosal and mechanical barriers, inhibit the growth of specific harmful bacteria, and are involved in the immune response within the gut. Since the identification of the bile acid receptor FXR, there has been a growing interest in the role of bile acids as signaling molecules that influence cell growth and immune responses. The interaction between bile acids and their key receptors, FXR and TGR5, along with the intestinal barrier, is crucial for maintaining intestinal barrier integrity.
Gut Microbiome Modulation
Recent evidence suggests that changes in microbiota composition directly affect the metabolism of bile salts. Bile salts, including TUDCA, play a role in intestinal homeostasis by controlling the size and composition of the intestinal microbiota. Changes in bile salt pool and composition due to changes in gut microbial composition may contribute to the pathogenesis of inflammatory bowel disease and metabolic disease, possibly through altered activation of TGR5 and FXR.
Pharmacokinetics (TUDCA)
About 65% of the oral dose of TUDCA is absorbed and then undergoes first-pass metabolism in the liver followed by extensive enterohepatic circulation. Administration of bile acids such as UDCA and TUDCA results in a change in the overall serum bile acid concentration — between 1.9- and 8-fold — and alters the composition of the bile acid pool. TUDCA and ursodeoxycholic acid are highly hydrophilic bile acids synthesized in the liver, which can cross the blood–brain barrier.
Body Systems and Health Areas
- Hepatobiliary system: cholestatic liver diseases, primary biliary cholangitis, gallstone dissolution, liver cirrhosis
- Gastrointestinal system: fat digestion, fat malabsorption, postcholecystectomy syndrome, bile acid diarrhea, irritable bowel syndrome
- Endocrine and metabolic system: glucose homeostasis, insulin sensitivity, energy expenditure, obesity
- Nervous system: neurodegenerative disease (ALS, Alzheimer's disease, Parkinson's disease — primarily preclinical evidence)
- Immune system: intestinal immune regulation, inflammatory bowel disease (early evidence)
- Nutritional: absorption of fat-soluble vitamins A, D, E, and K
Scientific Evidence by Area of Use
1. Cholestatic Liver Disease and Primary Biliary Cholangitis (PBC)
This is the area of strongest and most established clinical evidence for bile acid therapy. The application of ursodeoxycholic acid (UDCA) for cholestatic liver diseases began in the second half of the 20th century. Currently, UDCA is regarded as an effective first-line treatment for primary biliary cholangitis (PBC), the most common chronic cholestatic liver disease, and is also applied in other cholestatic disorders, including primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.
For TUDCA specifically, a pivotal multicenter randomized double-blind clinical trial compared TUDCA and UDCA in Chinese patients with PBC. In that trial, 199 PBC patients were randomly assigned to either 250 mg TUDCA or 250 mg UDCA three times per day for 24 weeks. The primary endpoint was the percentage of patients achieving a serum alkaline phosphatase (ALP) reduction of more than 25% from baseline. At week 24, 75.97% of patients in the TUDCA group and 80.88% in the UDCA group achieved this endpoint (P = 0.453), while the percentage of patients with ALP levels declining more than 40% was 55.81% in the TUDCA group and 52.94% in the UDCA group (P = 0.699). The conclusion was that TUDCA is safe and as efficacious as UDCA for the treatment of PBC, and may be better at relieving symptoms than UDCA.
Randomized controlled trials have shown that TUDCA treatment improves liver function in patients with liver cirrhosis, HCV-related chronic hepatitis, and cholestasis. These studies have shown that TUDCA drastically lowers serum liver enzymes that are markers of liver inflammation (ALT, AST, and ALP).
Evidence strength: Strong for UDCA in PBC (first-line guideline-recommended therapy); strong for TUDCA as non-inferior to UDCA in PBC based on multicenter RCT data.
2. Gallstone Dissolution
TUDCA is used for the treatment of cholesterol gallstones and has been used for the treatment of cholestatic liver diseases including primary biliary cirrhosis, pediatric familial intrahepatic cholestasis, primary sclerosing cholangitis, and cholestasis due to cystic fibrosis. Chenodeoxycholic acid (CDCA) was the first bile acid used in the therapy of cholesterol biliary calculosis. It inhibits hepatic cholesterol synthesis (via HMGCoA reductase), so that a bile undersaturated with cholesterol is produced; moreover, the high detergent action of CDCA makes easier the disintegration of gallstones into the bile in micellar solution. However, its chronic use causes side effects including diarrhea and raised hepatic transaminase levels that limit its therapeutic utility.
Evidence strength: Well-established for both CDCA and UDCA/TUDCA; regulatory approvals exist in multiple jurisdictions.
3. Postcholecystectomy Digestive Support
The evidence for supplemental bile salts after gallbladder removal is largely mechanistic and observational, but the rationale is strong: if the body no longer releases concentrated bile with meals, supplementing bile salts at mealtime bridges that gap. There is no large-scale RCT proving that everyone after gallbladder removal needs supplementation. However, ox bile supplements have been studied and found to improve fat absorption in patients with depleted bile salt pools, specifically in those who have lost more than 100 cm of ileum, without reports of significant adverse effects.
A clinical trial using tauroursodeoxycholic acid at 500 mg per day showed reduced dyspepsia in cholecystectomized patients. Without a gallbladder concentrating and timing bile release, fat digestion becomes less efficient, which directly impairs absorption of fat-soluble vitamins A, D, E, and K. Vitamin D deficiency is particularly common post-cholecystectomy.
Evidence strength: Preliminary to moderate. One small controlled trial for dyspepsia relief; larger RCT evidence is lacking for ox bile extract specifically. The mechanistic rationale is well supported.
4. Insulin Sensitivity and Glucose Metabolism
In a randomized controlled trial of 20 obese men and women with insulin resistance, TUDCA treatment at 1,750 mg/day for 4 weeks resulted in a 30% increase in insulin sensitivity in the liver and muscle, as reported by Kars et al. (2010). Although TUDCA is reported to decrease ER stress, markers of ER stress were not altered in these subjects from adipose tissue biopsy.
Consistent with rodent models, there is sufficient evidence suggesting that bile acid signaling has been improved in both human patients and animal models with bariatric surgery. Patients with beneficial improvements including body weight loss and reduced blood glucose levels exhibited high levels of circulating bile acids and enhanced GLP-1 secretion.
Studies in rodents suggest an important role for TGR5 in GLP-1 secretion, insulin sensitivity, and energy expenditure. However, evidence of effects on these processes from human studies is less convincing. Overall, there is a complex and paradoxical relationship between bile acids and metabolism.
Evidence strength: The insulin-sensitivity effect from one small RCT is promising but requires replication in larger trials. The mechanistic evidence (TGR5/GLP-1/FXR signaling) is well characterized in preclinical models; translation to humans remains an active research area.
5. Amyotrophic Lateral Sclerosis (ALS) and Neurodegeneration
In recent years, hydrophilic bile acids, particularly TUDCA, have shown important anti-apoptotic and neuroprotective activities, with experimental and clinical evidence suggesting their possible therapeutic use as disease-modifiers in neurodegenerative diseases. Experimental evidence derives from animal models of Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and cerebral ischemia. Preclinical studies indicate that TUDCA exerts its effects by regulating and inhibiting the apoptotic cascade, reducing oxidative stress, protecting mitochondria, producing an anti-neuroinflammatory action, and acting as a chemical chaperone to maintain correct protein folding.
A phase II study administered UDCA to 18 ALS patients randomly assigned to receive 15, 30, or 50 mg/kg UDCA daily. The drug was well-tolerated by all subjects at all doses. UDCA reached meaningful serum levels after oral intake and was also detected in the CSF of treated patients. A subsequent oral soluble UDCA formulation at 3.5 g/140 mL/day was tested for 3 months on 64 ALS patients in a phase II crossover trial, which reported a possible beneficial effect of UDCA on functional decline in ALS.
Two independent phase II studies — using TUDCA solo or combined with sodium phenylbutyrate — showed similar efficacy in slowing disease progression measured by functional scales. One open-label follow-up TUDCA plus sodium phenylbutyrate study suggested a benefit on survival.
However, the phase III results did not confirm this promise: topline data from a large-scale phase III study (NCT03800524) showed that TUDCA failed to distinguish itself from placebo in slowing disease progression among patients with ALS. The phase III study followed a successful proof-of-concept phase IIb study, where treatment with TUDCA resulted in about a 7-point less per-year decline in the ALS Functional Rating Scale–Revised (ALSFRS-R) compared with riluzole alone — corresponding to a prolongation of median survival of 4–5 months.
Evidence strength: Phase II signals were encouraging, but the completed phase III trial did not confirm efficacy for slowing ALS progression. The neuroprotective mechanisms remain of scientific interest, but TUDCA currently lacks proven clinical benefit in ALS.
6. Liver Transplantation
One RCT and a systematic review of 7 additional RCTs reported on UDCA or TUDCA use post-transplantation for prevention of complications in the acute transplant period in 447 patients. UDCA/TUDCA doses ranged from 10–15 mg/kg/day for 1–6 months. In all trials, bile acids were initiated within the first week post-transplant. One trial found that administration of bile acids for the first 4 weeks post-liver transplant resulted in improvement in ALT, AST, and GGT within 7 days, with no changes in bilirubin or ALP.
Evidence strength: Moderate; RCT evidence exists but is heterogeneous in outcomes, and benefits are inconsistent across markers.
7. Cholesterol Reduction
Higher doses of TUDCA treatment — 1,000 or 1,500 mg/day for 6 months — decreased both total and HDL cholesterol compared to baseline, while the low dose of 500 mg/day showed no change. Change ratios for total cholesterol were 1.01, 0.94, and 0.89 for the 500, 1,000, and 1,500 mg groups respectively. There were no placebo controls in this study. The changes in cholesterol levels may be explained by improvement of cholestasis and also by a decrease in cholesterol absorption.
Evidence strength: Weak to moderate; the relevant study lacked a placebo control, and results are confounded by cholestasis improvement.
Dosage Forms and Reported Doses
Bile salt supplements are available in several forms:
- Capsules and tablets (ox bile extract, TUDCA, UDCA)
- Powders (TUDCA powder for oral solution)
- Oral solutions
Doses reported in published clinical studies include:
- In the PBC multicenter RCT, patients received 250 mg TUDCA three times per day (750 mg/day total) for 24 weeks.
- In the insulin resistance RCT, TUDCA was administered at 1,750 mg/day for 4 weeks.
- For cholestatic liver disease in Europe, TUDCA is used at 10–20 mg/kg/day depending on indication.
- In liver transplantation studies, UDCA/TUDCA doses ranged from 10–15 mg/kg/day for 1–6 months.
- In ALS phase II, doses of 15, 30, or 50 mg/kg UDCA daily were tested.
- A phase II ALS double-blind placebo-controlled study used TUDCA at 1 g twice daily (2 g/day total) for 54 weeks.
- In cholestasis studies, doses of 500, 1,000, and 1,500 mg/day of TUDCA for 6 months were evaluated.
- A postcholecystectomy clinical trial used tauroursodeoxycholic acid at 500 mg per day.
Safety Considerations and Drug Interactions
General Tolerability
Clinical studies performed on patients with different medical conditions over the last years unanimously report that the chronic administration of hydrophilic bile acids is safe and well-tolerated. Several studies indicate that 1.75 g/day of TUDCA is a safe and likely effective dose for insulin resistance. In one study, 10 obese, insulin-resistant adults received 1.75 g/day of TUDCA for 4 weeks with no adverse events. A cohort of subjects with primary biliary cirrhosis were treated with 500–1,500 mg/day of TUDCA for 6 months, with diarrhea reported as the only side effect.
Chronic toxicity has been studied in dogs for up to 26 weeks with treatment of up to 400–600 mg/kg/day (approximately 30 times the proposed dose) with no observed toxicity. Rats treated with 2–20 times the proposed dose showed no evidence of carcinogenic effects after 24 months of treatment.
Diarrhea as Primary Side Effect
The intraluminal effects of relatively high concentrations of dihydroxy bile acids result in diarrhea; conversely, neutralization of the effects of such bile acids results in relief of bile acid diarrhea. Bile acids have effects on the intestine that are similar to those of other anionic surfactants and stimulant laxatives; they reduce net absorption of water and electrolytes and cause diarrhea if they escape ileal absorption.
Specific Bile Acid Toxicity: Lithocholic Acid and CDCA
Lithocholic acid, a monohydroxy secondary bile acid, is formed by bacterial 7-dehydroxylation of the primary bile acid CDCA and of the secondary bile acid UDCA. Lithocholic acid and its precursor CDCA are toxic when fed to the rabbit, rhesus monkey, and baboon, but not when CDCA or UDCA is used for therapeutic purposes in humans. The species-specific toxicity of lithocholic acid in humans is explained by efficient sulfation of lithocholic acid in humans, which detoxifies the compound.
Animal feeding studies demonstrated clear toxicity with lithocholic, cholic, deoxycholic, and chenodeoxycholic acid in mice, but little or no toxicity with ursodeoxycholic acid.
CDCA is moderately toxic at both the intestinal and hepatic level; it is metabolized in the organism to lithocholic acid, a highly hepatotoxic bile acid.
High-Dose UDCA Concerns
UDCA has demonstrated "unanticipated" toxicity at high doses of 28 mg/kg/day in primary sclerosing cholangitis, with more than double the number of deaths and eligibility for liver transplantation compared to the control group, necessitating trial termination in North America. This high-dose toxicity does not apply to the lower therapeutic range used in PBC.
Contraindications
Active liver disease or biliary obstruction represents a contraindication to OTC bile salt supplementation. Bile acid supplementation in cholestasis is a clinical decision, and prescription ursodeoxycholic acid is the appropriate intervention, not over-the-counter ox bile.
Drug and Nutrient Interactions
- Bile acid sequestrants: Bile acid sequestrants such as cholestyramine and colesevelam have an antagonistic mechanism with bile salt supplements; ox bile delivers bile salts while sequestrants bind them. This combination should be used only under clinician guidance.
- Fat-soluble vitamins and medications: Ox bile improves micellar formation; absorption of fat-soluble vitamins (A, D, E, K) taken concurrently may be enhanced. Similarly, oral fat-soluble medications may be subject to enhanced absorption, which is clinically relevant for medications with narrow therapeutic windows.
- Anticoagulants: The interaction with anticoagulants such as warfarin is indirect, mediated via enhanced vitamin K absorption; INR should be monitored if bile salt intake is variable.
- Antiretroviral drugs: There are no known interactions between bile acids and antiretroviral drugs.
- Pregnancy and lactation: No controlled human data exists for ox bile supplementation during pregnancy or breastfeeding; it is generally avoided at supplemental doses without obstetric guidance.
Bile Acid Diarrhea as Adverse Effect
With the liver frequently releasing bile into the small intestine after gallbladder removal, there is the possibility that the body cannot keep up with the demand for the re-absorption of all bile salts, meaning that excess bile salts can make their way further into the colon. Urgency, loose stool, diarrhea, and cramping can often be signs of too many bile salts reaching the colon unabsorbed.
References
Go back